Morphic Announces Participation in 2022 Wells Fargo Healthcare Conference

Morphic Therapeutic (NASDAQ: MORF) announced that its management will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 8 at 10:25 AM ET.

Rhea-AI Summary

Morphic Therapeutic (NASDAQ: MORF) announced that its management will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 8 at 10:25 AM ET. A live webcast will be accessible on the Investor section of the company’s website, with an archived replay available post-conference. Morphic is focused on developing a new generation of oral integrin therapies aimed at treating serious chronic diseases such as autoimmune disorders, cardiovascular issues, and cancer, leveraging its proprietary MInT technology platform in collaboration with Janssen and Schrödinger.

Argus Session date unavailable

+5.38% session move Open Argus

Details

News Market Reaction – MORF

The recorded move for MORF in the trading session of this news was +5.38%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that members of its management team will participate in a fireside chat at the Wells Fargo Healthcare Conference on Thursday, September 8^that 10:25 AM ET.

A live webcast of the event will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. In collaboration with Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Morphic Therapeutic's fireside chat at the Wells Fargo Healthcare Conference?

Morphic Therapeutic's fireside chat is scheduled for September 8 at 10:25 AM ET.

Where can I watch the Morphic Therapeutic fireside chat?

The fireside chat can be watched live on the Investor section of Morphic Therapeutic's website.

What is Morphic Therapeutic's focus in drug development?

Morphic Therapeutic focuses on developing oral integrin therapies for serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases.